Q4 26 EPS Adjusted
$2.91
BEAT +20.22%
Est. $2.42
Includes a one-time positive impact of $0.31 per share from recognition of IEEPA tariff refunds ($100 million pre-tax net operating profit impact in the GMPD segment)
Q4 26 Revenue
$63.67B
MISS 2.20%
Est. $65.11B
vs S&P Since Q4 26
-2.2%
TRAILING MARKET
CAH -2.0% vs S&P +0.3%
Full Year 2026 Results
FY 26 EPS
$11.26
BEAT +4.49%
Est. $10.78
FY 26 Revenue
$254.25B
MISS 0.62%
Est. $255.82B
Market Reaction
Did CAH Beat Earnings? Q4 2026 Results
Cardinal Health posted a sharply mixed fiscal fourth-quarter 2026 report, delivering a substantial earnings beat alongside a revenue shortfall that left analysts weighing the quality of the profit surge. Adjusted non-GAAP EPS came in at $2.91, cleari… Read more Cardinal Health posted a sharply mixed fiscal fourth-quarter 2026 report, delivering a substantial earnings beat alongside a revenue shortfall that left analysts weighing the quality of the profit surge. Adjusted non-GAAP EPS came in at $2.91, clearing the $2.42 consensus estimate by 20.22%, though the headline figure was meaningfully boosted by a one-time $100 million pre-tax benefit from IEEPA tariff refunds within the GMPD segment, contributing $0.31 per share to the quarter's result. Revenue of $63.67 billion rose 5.8% year over year but fell short of the $65.11 billion consensus by 2.20%, with GMPD volumes under pressure and tariff refund pass-throughs to customers weighing on the segment's top line. The Pharmaceutical and Specialty Solutions segment remained the primary engine, generating $58.85 billion in revenue, up 6%, on continued brand and specialty pharmaceutical momentum. Looking ahead, Cardinal Health guided fiscal 2027 non-GAAP EPS to $12.40 to $12.60, reflecting 13% to 15% growth off the adjusted prior-year base, with recently completed acquisitions of Strive Medical and AdaptHealth's Diabetes Health business factored into that outlook.
Key Takeaways
- • Brand and specialty pharmaceutical sales growth from existing customers drove Pharma segment revenue growth
- • Positive generics program performance contributed to Pharma segment profit growth
- • IEEPA tariff refunds of $100 million boosted GMPD segment profit
- • All five operating segments grew profit double-digits for the full fiscal year
- • Lower non-GAAP effective tax rate (22.5% vs 26.3% in prior year quarter)
- • Lower share count from in-year share repurchases
CAH Forward Guidance & Outlook
Cardinal Health provided FY2027 non-GAAP EPS guidance of $12.40 to $12.60, representing 13% to 15% growth off the adjusted FY2026 base (excluding IEEPA tariff refund benefit). Pharmaceutical and Specialty Solutions segment revenue is expected to grow 3% to 5% with segment profit growth of 8% to 11%. GMPD segment revenue is expected to grow 2% to 4% with segment profit of $200 million to $220 million. Other segment revenue is expected to grow 11% to 13% with segment profit growth of 15% to 18%. Interest and other expense is guided at $240 million to $290 million, non-GAAP effective tax rate of 19.0% to 20.0%, diluted weighted average shares outstanding of approximately 233 million, share repurchases of approximately $1 billion, capital expenditures of approximately $700 million, and non-GAAP adjusted free cash flow of $3.5 billion to $4.0 billion. Guidance reflects the estimated impact of the recently completed acquisition of Strive Medical and the announced acquisition of AdaptHealth's Diabetes Health business.
CAH YoY Financials
Q4 2026 vs Q4 2025, source: SEC Filings
CAH Revenue by Segment
With YoY comparisons, source: SEC Filings
“Fiscal 2026 was a standout year for Cardinal Health and I am pleased with our strong fourth quarter results. The broad-based operational strength for the year, with all five of our operating segments growing profit double-digits, even before recognition of IEEPA tariff recoveries in GMPD, reflects the disciplined execution of our strategy and our investments for growth. We enter Fiscal 2027 with momentum and confidence in our ability to deliver continued shareholder value creation.”
— Jason Hollar, Q4 2026 Earnings Press Release
CAH Earnings Trends
CAH vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CAH EPS Trend
Earnings per share: estimate vs actual
CAH Revenue Trend
Quarterly revenue: estimate vs actual
CAH Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 26 BEAT FY Includes a one-time positive impact of $0.31 per share from recognition of IEEPA tariff refunds ($100 million pre-tax net operating profit impact in the GMPD segment) | $2.42 | $2.91 | +20.22% | $63.67B | -2.20% |
| FY Full Year | $10.78 | $11.26 | +4.49% | $254.25B | -0.62% |
| Q3 26 BEAT | $2.79 | $3.17 | +13.70% | $60.94B | -2.19% |
| Q2 26 BEAT | $2.37 | $2.63 | +11.17% | $65.63B | +0.60% |
| Q1 26 BEAT | $2.17 | $2.55 | +17.33% | $64.01B | +8.00% |
| Q4 25 MISS FY | $2.18 | $2.08 | -4.70% | $60.16B | +1.26% |
| FY Full Year | $9.43 | $8.24 | -12.65% | $222.58B | -0.33% |
| Q3 25 BEAT | $2.15 | $2.35 | +9.36% | $54.88B | -0.78% |